Clinical Report: Effectiveness and Safety of Brief Antibiotic Treatment for CAP

Overview

This meta-analytic review evaluates the efficacy and safety of short-course antibiotic therapy (≤5 days) compared to long-course therapy (>5 days) for adults with community-acquired pneumonia (CAP).

Background

Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality, necessitating effective antibiotic treatment. Optimizing antibiotic duration is crucial for antimicrobial stewardship, as prolonged therapy can lead to adverse events and contribute to antimicrobial resistance.

Data Highlights

Key Findings

• Short-course therapy (≤5 days) achieved comparable clinical success to long-course therapy (>5 days).
• There was no significant difference in bacteriological and radiological success between the two regimens.
• All-cause mortality rates were similar for both treatment durations.
• Short-course regimens were associated with a marginally higher risk of mild treatment-related adverse events.
• A non-significant downward trend in treatment-related serious adverse events was observed with short-course therapy.

Clinical Implications

Clinicians should consider the findings of this review when evaluating antibiotic treatment duration for adults with CAP.

Conclusion

Short-course antibiotic therapy for CAP demonstrates comparable efficacy to longer regimens.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. conexiant — Short Antibiotics Match Outcomes in Pneumonia
3. Infection — Comparison of 7-Day versus 14-Day Antimicrobial Therapy in Bacteremia Patients: A Meta-Analysis of Randomized Controlled Trials
4. conexiant — Antibiotics May Not Help Mild COVID
5. Open Forum Infectious Diseases — Comparative Analysis of Cefepime and Carbapenem Treatment for Invasive Infections Caused by Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-Analysis
6. Short Antibiotics Match Outcomes in Pneumonia
7. Comparison of 7-Day versus 14-Day Antimicrobial Therapy in Bacteremia Patients: A Meta-Analysis of Randomized Controlled Trials
8. Antibiotics May Not Help Mild COVID
9. Diagnosis and Treatment of Adults with Community-acquired Pneumonia
10. https://academic.oup.com/ajrccm/article/212/1/24/8435770
11. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia - PMC
12. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial | Infectious Diseases | JAMA Internal Medicine | JAMA Network
13. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial - PubMed
14. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study - PMC
15. Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis - PMC
16. Short Versus Longer Antibiotic Duration for Community-Acquired Pneumonia : A Multicenter Target Trial Emulation - PubMed